Shares of psychedelics companies are trading lower after an FDA panel, on Tuesday, rejected the approval of MDMA therapy for people with PTSD.
Portfolio Pulse from Benzinga Newsdesk
Shares of psychedelics companies are trading lower after an FDA panel rejected the approval of MDMA therapy for PTSD.
June 05, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Compass Pathways' stock is likely to be negatively impacted by the FDA's rejection of MDMA therapy for PTSD.
As a company involved in psychedelics, Compass Pathways is likely to see a negative impact on its stock price due to the FDA's decision.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Cybin Inc.'s stock is expected to decline following the FDA's decision to reject MDMA therapy for PTSD.
Cybin Inc., being a psychedelics company, will likely experience a drop in its stock price due to the FDA's rejection.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Mind Medicine's stock is likely to be negatively affected by the FDA's rejection of MDMA therapy for PTSD.
Mind Medicine, as a psychedelics company, is expected to see a negative impact on its stock price following the FDA's decision.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80